Rheumatology

Ustekinumab-kfce is planned for launch in February 2025 according to a previous settlement and license agreement with Janssen.

Findings from PsABIOnd can help reassure clinicians of similar efficacy between treatment choices.

At the highest dose levels, mean plasma urate levels remained below 6.0 mg/dL for up to 12 weeks.

Patients in the anifrolumab arm also had lower rates of damage accrual.

The findings are especially important as differences in disease characteristics and outcomes between male and female patients become more clear.

Lowering serum urate level to less than 6 mg/dL was not linked to an elevated risk of severe or end-stage kidney disease progression in patients with gout.

This post-hoc analysis demonstrated an association between work productivity and stringent disease control criteria for those with psoriatic arthritis.

Hypovitaminosis D was more prevalent in patients with lupus nephritis compared to patients with systemic lupus erythematosus without kidney disease.

Clinically meaningful increases in patient-reported outcomes were identified after 3 doses of SEL-212 and strengthened after 3 additional doses.

These data, presented at ACR 2024, demonstrate that response was maintained at 2 years among those with psoriatic arthritis who responded to bimekizumab at Week 16.

The Urate-Lowering Therapy to Acute Treatment Ratio (ULTrA) was linked to fewer gout-related hospital admissions.

Infusion reaction rates and serum level lowering were similar between 120-minute and 60-minute infusion cohorts in the phase 4 AGILE study.

Clowse discussed findings from the phase 3 PHOENYCS GO trial presented at the 2024 ACR Convergence.

Data from 2 studies presented at ACR 2024 demonstrate the potential of AI to improve access to quality rheumatological assessments.

Over half of patients treated with LEVI-04 had at least a 50% reduction in pain and over 25% had at least a 75% reduction.

The phase 3 PHOENYCS GO trial met its primary endpoint in achieving BICLA response at week 48 compared with placebo.

Over one-third of participants had had inadequate responses or intolerance to at least 3 prior b/tsDMARDs.

However, fewer patients experienced flares in the tofacitinib group than in the placebo group, among other positive findings.

Just discussed data from 2 studies demonstrating efficacy of AI assessment compared to clinician assessment.

Findings from the first and only controlled study for macrophage activation syndrome were presented at the ACR Convergence.

Gandhi discussed examining social security disability rates and how SSD criteria may clash with a trait disease like fibromyalgia.

Troum discussed positive efficacy and safety findings from the phase 4 AGILE study.

Schett discussed findings from 2 early studies of CD19 CAR T-cell therapy.

A-319 has been well-tolerated so far and dose-escalation is ongoing in the phase 1 trial.

Stone discussed findings from the first randomized, double-blind, placebo-controlled trial for IgG4-related disease.

People who used GC for over 2 years and 3 years had elevated risks of CVD and infection-related mortality, respectively, that never returned to pre-GC use levels.

IL-18 levels were consistently lower across participants with different SARDs, remission status, and COVID-19 disease characteristics.

This clinical quiz, our first in a series of 3, focuses on recommendations for specific vaccines from the 2022 ACR vaccination guidelines.

While an effective and promising strategy for chronic pain relief, more research on long-term cannabis usage is needed.

People with diabetes, kidney stones, damaged joints, high uric acids, and daily use of NSAID were more likely to develop CKD than others.